{
  "pmcid": "5052204",
  "sha256": "4074eefa9d9316569da8fadc04439e0fc6db9a37fdb0b26670fc8c9de01342da",
  "timestamp_utc": "2025-11-09T22:45:03.478973+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.771990846681927,
    "reading_ease": 22.898581235697947,
    "word_count": 207
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Tobramycin-Impregnated Bone Cement in Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "15 patients undergoing primary TKA were randomly assigned"
      },
      "Participants": {
        "score": 1,
        "evidence": "Conducted at a single center"
      },
      "Intervention": {
        "score": 2,
        "evidence": "intervention group (n=10) receiving tobramycin-impregnated bone cement or the control group (n=5) receiving standard intravenous tobramycin"
      },
      "Objective": {
        "score": 1,
        "evidence": "aimed to evaluate the efficacy of tobramycin-impregnated bone cement"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was intraarticular tobramycin concentration."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was performed using a blinded envelope method."
      },
      "Blinding": {
        "score": 1,
        "evidence": "blinded envelope method"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "15 patients undergoing primary TKA were randomly assigned"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "intervention group (n=10) receiving tobramycin-impregnated bone cement or the control group (n=5)"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The intervention group showed significantly higher intraarticular tobramycin levels at 6 hours (median=31.8 μg/mL, p=0.002), 24 hours (median=17.1 μg/mL, p=0.002), and 48 hours (median=6.8 μg/mL, p=0.02) compared to the control group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not disclosed."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}